Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

254
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
254
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

216
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
216
Pneumonia IV: Management01:28

Pneumonia IV: Management

466
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
466
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

340
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
340

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of Vitamin D Replacement with a High-Dose Treat-to-Goal Strategy.

Nutrients·2026
Same author

C-type natriuretic peptide as mediator of growth in the absence of growth hormone: Unraveling the mystery of the growth without GH syndrome.

Hormones (Athens, Greece)·2025
Same author

Novel Treatments, Approaches, Prevention Strategies, and Insights in Pediatric, Adolescent, and Gynecological Endocrinology.

Children (Basel, Switzerland)·2025
Same author

Endocrine circuitry in autism spectrum disorders: A systematic review of mechanistic insights and clinical implications.

Neuroscience·2025
Same author

Dramatic Deterioration of Subclinical Hyperparathyroidism in Children and Adolescents During the Post-COVID-19 Period.

Diseases (Basel, Switzerland)·2025
Same author

The significance of ophthalmological evaluation in the correct diagnosis of pediatric insulin-dependent diabetes mellitus: lessons from novel WFS1 variants.

Diabetes & metabolism·2025

Related Experiment Video

Updated: Sep 26, 2025

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

81.1K

Rifampicin for COVID-19.

George D Panayiotakopoulos1, Dimitrios T Papadimitriou2

  • 1Department of Clinical Pharmacology, University of Patras Medical School, Rion 26504, Greece.

World Journal of Virology
|April 18, 2022
PubMed
Summary

Rifampicin shows promise as a potential treatment and preventative measure for COVID-19. Further research into nebulized lung administration could enhance its effectiveness and minimize side effects.

Keywords:
Antiviral activityCOVID-19RNA polymeraseRifampicinSARS-CoV-2

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K

Related Experiment Videos

Last Updated: Sep 26, 2025

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

81.1K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K

Area of Science:

  • Pharmacology
  • Virology
  • Infectious Diseases

Background:

  • Coronavirus disease-2019 (COVID-19) lacks specific antiviral treatments despite widespread vaccination efforts.
  • Rifampicin, an essential medicine, possesses known antiviral properties against RNA polymerase-dependent viruses.
  • Previous research indicates rifampicin's direct selective antiviral effect on viruses like SARS-CoV-2.

Purpose of the Study:

  • To evaluate the potential of rifampicin as a repurposed drug for COVID-19 treatment and chemoprophylaxis.
  • To explore the mechanism of rifampicin's antiviral action against SARS-CoV-2.
  • To investigate the feasibility of nebulized lung administration for enhanced efficacy.

Main Methods:

  • Review of existing literature on rifampicin's antiviral properties.
  • Analysis of rifampicin's mechanism of action, including inhibition of viral protein synthesis and polymerase.
  • Consideration of administration routes, particularly local lung delivery via nebulization.
  • Evaluation of in silico studies identifying rifampicin as a potential COVID-19 therapeutic.

Main Results:

  • Rifampicin demonstrates a direct selective antiviral effect on viruses with RNA polymerase, including SARS-CoV-2.
  • The drug inhibits late viral protein synthesis, virion assembly, and viral polymerase.
  • Local administration, such as nebulization, may increase drug concentration at infection sites and reduce systemic side effects.
  • In silico studies identified rifampicin as a promising candidate for drug repurposing in COVID-19.

Conclusions:

  • Rifampicin holds significant potential for the treatment and chemoprophylaxis of COVID-19, especially for high-risk individuals and healthcare personnel.
  • Nebulized lung administration of rifampicin warrants further investigation to optimize therapeutic outcomes.
  • Repurposing existing essential medicines like rifampicin offers a viable strategy for addressing unmet medical needs in emerging infectious diseases.